Sign in
Taking people in South KoreaNo phase

Blocking small knee blood vessels for knee osteoarthritis pain that persists despite usual care

Tests Nexsphere-F embolization in people with knee osteoarthritis whose pain stays uncontrolled.

Key facts

Who runs it
Next Biomedical Co., Ltd.
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis
Status
Recruiting
People taking part
20 people, planned
Started
23 Oct 2023
Planned end
Dec 2025
Type of study
Interventional
Treatments tested
  • Transcatheter Arterial Micro-Embolization
Record updated
2 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults over 50 years with knee osteoarthritis (wear-and-tear arthritis). Their knee pain must still be poorly controlled after usual treatments. They will have Nexsphere-F embolization, which blocks small blood vessels.

Age
Over 50 years (minimum age 50 Years)
Sex
All sexes
Disease stage
Knee osteoarthritis of Kellgren-Lawrence grade 2 to 3 on X-ray within 12 months. Pain score (VAS) above 50mm.
Earlier treatment
Must have had Glucosamine chondroitin sulfate, physical therapy and rehabilitation exercises, and hyaluronic acid knee injections for more than 12 weeks. Must keep current medicines and start no new knee pain treatments during the trial.

Main reasons for not taking part

  • Local infection, rheumatism or infectious arthritis, or life expectancy less than six months
  • Leg symptoms caused by narrowed or diseased arteries, such as pain when walking
  • Past knee replacement surgery
  • Severe iodine allergy, INR 2.5 or platelets less than 30,000, or eGFR less than 45 within the last 60 days
  • Pregnant women, or people who cannot have MRI scans

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Those who fall under Kellgren-Lawrence grade 2 to 3 according to the criteria in accordance with ACR guidelines and X-ray findings used within 12 months
  • VAS score exceeding 50mm
  • An adult male and female over 50 years of age
  • Preservative therapy Glucosamine chondroitin sulfate/physiological therapy and rehabilitation exercises, and joint injections of hyaluronic acid for more than 12 weeks
  • A person who agrees to maintain existing medication treatments during the clinical trial period but does not receive additional medication or new conservative treatments for knee osteoarthritis pain management

Who cannot take part

  • A person who has not had knee microfracture surgery for more than 10 years
  • A locally infected patient
  • A person with symptoms of lower extremities that are considered secondary to atherosclerosis or arterial vascular disease (ex: claudication ischemic rest pain)
  • Anaphylaxis-causing iodine allergy
  • INR 2.5 or less than 30,000 platelets
  • Patients with renal dysfunction or impaired renal function who have been diagnosed with less than 45 GFR (eGFR) within the last 60 days
  • A person whose life expectancy is less than six months
  • A person diagnosed with rheumatism or infectious arthritis
  • A person who has undergone knee arthroplasty
  • Those who have a taboo on MR videos
  • Pregnant women
  • Other cases where it is deemed inappropriate to participate in this clinical trial at the discretion of the researcher

Where in South Korea

  • Severance hospitalSeoul, South KoreaContact: Hyuckmin KwonTaking people

About the trial

What the trial wants to find out

Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the therapeutic effect and safety of Nexsphere-F embolization for patients who need additional treatment because pain is not controlled even if conventional treatments are taken.

The group in the trial

  • Transcatheter Arterial Micro-EmbolizationTreatment being tested

    If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Arm, Single Center, Open Label , Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro Embolization (TAME) Using Nexsphere F in Patients With Knee Degenerative Osteoarthritis
Plain-language title
Blocking small knee blood vessels for knee osteoarthritis pain that persists despite usual careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
2 April 2025